With its shares down by more than 22% in the last 12 months, it's clear that Biogen (NASDAQ: BIIB) isn't the high-flying growth stock that it used to be. Since its failed attempt over the last year to get its fiercely criticized Alzheimer's disease drug Aduhelm approved for sale, the company's troubles have turned from bad to worse. Revenue and earnings from its core drug products are both down sharply over the last three years.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting